<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01842191</url>
  </required_header>
  <id_info>
    <org_study_id>FOMS</org_study_id>
    <nct_id>NCT01842191</nct_id>
  </id_info>
  <brief_title>Efficacy of Fish Oil in Multiple Sclerosis</brief_title>
  <acronym>EFOMS</acronym>
  <official_title>Efficacy of Fish Oil on Serum TNFα, IL-1β, IL-6, Oxidative Stress Markers in Multiple Sclerosis Treated With Interferon Beta 1-b</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present work was to evaluate the efficacy of fish oil supplementation on serum
      proinflammatory cytokines levels, oxidative stress markers and disease progression in MS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current research findings suggest that Omega-3 polyunsaturated fatty acids (PUFA) such as
      eicosahexanoic acid (EPA) and docosahexaenoic acid (DHA) contained in fish oil may have
      anti-inflammatory, antioxidant and neuroprotective effects. The aim of the present work was
      to evaluate the efficacy of fish oil supplementation on serum proinflammatory cytokines
      levels, oxidative stress markers and disease progression in MS. 50 patients with
      relapsing-remitting MS were enrolled. The experimental group received orally 4 g/day of fish
      oil for 12 months. The primary outcome was serum TNFα levels; Secondary outcomes were IL-1β,
      IL-6, nitric oxide catabolites, lipoperoxides, progression on the expanded disability status
      scale (EDSS) and annualized relapses rate (ARR).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TNF alpha</measure>
    <time_frame>3 months</time_frame>
    <description>Serum TNF alpha levels, at baseline, 3, 6, 9 and 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IL-1 beta, IL-6, Lipoperoxides, nitric oxide</measure>
    <time_frame>3 months</time_frame>
    <description>Serum IL-1 beta, IL-6, Lipoperoxides, nitric oxide levels at baseline, 3, 6, 9 and 12 months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Expanded Disability Status Scale (EDSS) and Annualized rate of relapses (ARR)</measure>
    <time_frame>6 months</time_frame>
    <description>EDSS and ARR at baseline, 6 months and 12 months</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Relapsing- Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Fish oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil</intervention_name>
    <description>Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.</description>
    <arm_group_label>Fish oil</arm_group_label>
    <other_name>PUFAS</other_name>
    <other_name>Omega 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients had clinically definite and magnetic resonance image supported MS

          -  Had at least one relapse in the year before entry into the study

          -  EDSS score of 0-5

          -  Treated with subcutaneous 250 μg interferon beta-1b (Betaseron, Bayer)

        Exclusion Criteria:

          -  they were taking another supplement

          -  had progressive forms of MS

          -  had history of severe depression

          -  had history of acute liver or renal dysfunction

          -  had history of tobacco, drug or alcohol abuse

          -  had intolerance, contraindication or allergy to fish oil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Genaro G Ortiz, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Social Security Mexican Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IMSS, Specialties Hospital, Neurology Departament</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Ortiz GG, Macías-Islas MA, Pacheco-Moisés FP, Cruz-Ramos JA, Sustersik S, Barba EA, Aguayo A. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers. 2009;26(1):35-9. doi: 10.3233/DMA-2009-0602.</citation>
    <PMID>19242067</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2013</study_first_submitted>
  <study_first_submitted_qc>April 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <last_update_submitted>May 20, 2013</last_update_submitted>
  <last_update_submitted_qc>May 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Genaro Gabriel Ortiz</investigator_full_name>
    <investigator_title>Investigador titular D</investigator_title>
  </responsible_party>
  <keyword>R-R MS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Titanium dioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

